The results of this study rely only on the protein expression of cyclin A, and no functional assay to detect cyclin A/cdk2 kinase activity in vitro was performed. However, the tight correlation between cyclin A expression and BrdU incorporation favors the idea that the in vivo kinase activity in cyclin A-expressing cells was functional, as cells lacking this activity could not progress through the S phase. 7 According to the results of this study, there was no evidence of an accumulation of cyclin A-positive cells that are unable to progress through the S phase, and therefore lack BrdU incorporation, or of an accumulation of BrdU-positive cells that could not progress through the S phase because of deficient cyclin A expression.
In conclusion, this study revealed an undisturbed transition of ALL cells from the G1 to the S phase, with only a small percentage of cells triggered to enter the S phase. These findings are difficult to reconcile with an accumulation of ALL cells in the late G1 phase, as suggested from the hyperphosphorylation of pRb. Accordingly, the loss of differentiation is not the result of a commitment to complete the mitotic cycle. Although most pRb is phosphorylated to a degree that induces loss of nuclear tethering in pediatric ALL cells, part of this soluble pRb was still bound to E2F1, a fact that suggested a persistent repression of transcriptional activity. Together, loss of nuclear tethering with retention of the ability to bind E2F1 could reflect a partial inactivation of pRb functions, resulting in loss of differentiation without traversing the R point. This model is in agreement with a recent study demonstrating that the control of the R point occurs by a switching mechanism in the pRb-E2F pathway converting growth stimuli into an all-or-none E2F response. 8 It is possible that interfering with the mechanisms responsible for the partial inactivation of pRb functions in ALL cells could be the starting point for the development of a differentiation-inducing therapy. Retinoic acid receptors (RARs) are members of a much larger group of ligand-dependent transcription factors, the so-called nuclear receptors. In mammals, there are three distinct RAR subtypes: RARa, RARb and RARg. 1 RARs share a high sequence homology, but show distinct transcriptional properties and expression pattern, suggesting similar but not necessarily overlapping functions. In haematopoietic differentiation, for example, the function of RARg is uniquely required to maintain the stem cell compartment, whereas RARa seems to work primarily at later stages, favouring differentiation. 2 In acute promyelocytic leukaemia (APL), chromosomal translocations involve in 100% of cases the a-subtype of the RAR gene (RARa), on chromosome 17. These translocations lead to the synthesis of chimeric proteins: in 95% of the cases, the translocation partner is the PML (promyelocytic leukaemia) gene on chromosome 15, leading to the formation of PML-RARa fusion gene. 3 Both in vitro and in vivo studies have well defined the oncogenic roles of PML-RARa fusion protein in the pathogenesis of APL, acting as an altered RAR. 4 In our previous work, we studied the transcriptional and biological properties of chimeric constructs where PML was fused to RARb or RARg to generate the PML-RARb and PML-RARg fusion proteins (which do not exist in nature). Both chimeric proteins demonstrated similar properties to PML-RARa in vitro. 5 Here, we extended this analysis to determine directly whether PML-RARg (as a test case), like PML-RARa, is able to induce APL.
We used the same approach successfully used to show that PML-RARa can initiate leukaemia in vivo.
6 Murine haematopoietic progenitors (Lin À cells) were transduced with a retroviral vector, which encodes for PML-RARg, together with the green fluorescence protein (GFP). As control, we used Lin À cells infected with the empty vector, which express GFP only. The transduced cells were sorted by cytofluorimetry using the co-expressed GFP as a selection marker. From previous studies, we have observed that the levels of PML-RARg are equivalent to those obtained by transduction of PML-RARa. 5 Immediately after sorting, transduced cells were inoculated into lethally irradiated recipient mice. A group of eight mice were injected with control cells, whereas 14 mice were injected with PMLRARg-expressing cells (Figure 1a) . After 4 months, we measured the reconstitution levels of donor (GFP þ ) cells in all survived mice. All mice reconstituted with Lin À cell transduced with empty vector and those transduced with PML-RARg displayed a comparable level of donor cells in the peripheral blood (variable from 5 to 25%; data not shown). At 1 year after transplantation, 50% of the mice reconstituted with PML-RARg-expressing cells developed leukaemia, whereas all mice inoculated with control cells are still alive (Figure 1b ). In all cases tested, the disease was transplantable to secondary recipients (a hallmark of the leukaemic phenotype) with a minimal latency (4 weeks) and with characteristics identical to those observed in the primary recipient mice. Analysis of blasts cells confirmed that leukaemic cells are immature myeloid progenitors (large nuclei and large basophilic cytoplasm), with the morphology typically observed in leukaemia achieved upon PML-RARa expression (Figure 1c) . Fluorescence-activated cell sorting analysis of cell suspensions isolated from bone marrow and spleen tissues of different leukaemic mice showed a similar immunophenotype, characterized from a high expression level of surface markers CD34, c-kit, Mac-1 and Gr-1 (date not shown): these surface properties are indistinguishable from those seen in PML-RARa driven leukaemia. 5 We conclude therefore that PML-RARg is able to trigger leukaemia development in vivo. Notably, in our previous analysis of PML-RARa driven leukaemia, we have observed a shorter median latency (173 days), and a higher penetrance of the disease (75%). The disease phenotype is highly dependent on the level of expression of the transgene, and PML-RARa in some cases behaves as a weaker oncogene: 7 we tend therefore to interpret the differences observed as mainly to be ascribed to slight differences in expression among PML-RARa and PML-RARg, rather than authentic biological differences among the fusion proteins. APL is characterized by its unique responsiveness to retinoic acid (RA). RA induces differentiation of leukaemic blasts, and the treatment with pharmacological doses of RA lead to clinical remission of APL patients. 8 We examined therefore the in vivo response of PML-RARg leukaemic mice to RA. RA treatments resulted in a significantly (Po0.0003) longer mean survival: the minimum and the maximum survival time of the RA-treated leukaemic mice were 45 and 75 days, with a median of 54 days (Figure 2) . Starting from 5 days of therapy, the infiltration of the blasts, in various organs appeared reduced and the cells within the leukaemia fraction revealed signs of granulocytic differentiation (data not shown). As in PML-RARa, PML-RARg driven leukaemia is therefore sensitive to the differentiating effects of pharmacological doses of RA. Taken together, our studies show unequivocally that upon fusion with their oncogenic partnerFall RAR isoforms share an essentially identical leukemogenic potential, and are able to trigger a clinically identical disease. In the selection of RARa as the exclusive breakpoint in the human disease, factors must be involved which are more directly related to the probability of the recombinative event to occur (that is, vicinity of the chromosomes 15 and 17 vs the chromosomes where RARb and RARg are located; similar replication times for PML and RARa), rather than to the selection of the most potent oncogene. We believe thatFgiven the absence of APL cases due to RARb and RARg rearrangementsFthese topological constrains must have a critical role in defining the 'available oncogenes' that may actually trigger tumorigenesis in a target cell. 
